Info@ThinkPinkRocks.com

Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen

View article:
Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Share

Leave a Reply